Author： Phan Binh An P Toth Peter P
Publisher： Future Medicine
ISSN： 1758-4299
Source： Clinical Lipidology, Vol.8, Iss.2, 2013-04, pp. : 195-203
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Despite recent advances in the treatment of atherosclerotic heart disease, there remains a high residual risk of cardiovascular disease-related events, such as myocardial infarction, ischemic stroke and death. Intense research is underway worldwide to identify novel biomarkers that may better identify patients at risk for atherosclerotic disease and that could be used to guide the need for treatment, as well as its intensity. Epidemiologic studies have shown that increased levels of lipoprotein(a) (Lp(a)) are associated with a high risk of atherosclerotic cardiovascular disease. Pathologic and clinical evidence suggest that Lp(a) may be involved in the initiation and progression of atherosclerosis. A number of novel lipid therapies have proven to be effective in lowering Lp(a) levels. Additional research is needed to help quantify the cardiovascular benefits of incorporating Lp(a) testing into clinical practice and using therapies that lower its serum levels.
Related content
Access to resources
Recommend
Lipoprotein(a) and Thrombocytes: Potential Mechanisms Underlying Cardiovascular Risk
Pathophysiology of Haemostasis and Thrombosis, Vol. 35, Iss. 3-4, 2006-08 ,pp. :
By Aasvee K Jauhiainen M Kurvinen E Jordania R Sundvall J Ehnholm C
Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 59, Iss. 3, 1999-06 ,pp. :